Latest Sanofi Press Releases and News | Sanofi
WEBAug 26, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB3 days ago · FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Sanofi Enters Next Chapter of Play to Win Strategy | Sanofi
WEBOct 27, 2005 · Sanofi today provided a comprehensive update regarding its Play to Win strategy. This strategy continues to focus on the critical goals of executing transformative medicine and vaccines launches, driving agile and efficient resource deployment and enhancing R&D productivity.
Novavax shares soar on license deal with Sanofi at lofty valuation
WEBMay 10, 2024 · Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in most countries and use the COVID shot along with its own flu vaccines to develop...
Sanofi US News
WEBSep 16, 2024 · The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB2 days ago · Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS),. The results from the HERCULES Phase III trial (NCT04411641) showed that Bruton tyrosine kinase (BTK) inhibitor delayed the time to six-month disability progression by 31% compared to placebo.
Press Room - Sanofi US News
WEBJul 10, 2024 · Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022. Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented. Read more. Nov 30, 2022.
Press Room - Sanofi US News
WEBMar 23, 2023 · The randomized, Phase 3, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in 939 adults who were current or former smokers aged 40 to 80 years with moderate-to-severe COPD. All patients in the trial had evidence of type 2 inflammation, as measured by blood eosinophils ≥300 cells/µL.
Skip to content